Clinical Trials Details

NRG-GI005 COBRA (Colon)

A Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

Objective

Key eligibility: Resected stable Stage IIa T3N0 at least 12 LN examined; >12cm from anal verge; suitable for active surveillance.

Note: Temporarily closed to accrual on 7/5/23.

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms